Tivantinib (ARQ 197), a novel and highly selective non–ATP-competitive MET inhibitor, can inhibit human recombinant MET with a calculated inhibitory constant (Ki) of ~355 nM, and is currently in phase III cancer clinical trials (29, 30). Here, MET is linked to cancer.